Nvidia down for third day, Arm joins Nasdaq 100: Market Domination Overtime By apkyez
Nvidia down for third day, Arm joins Nasdaq 100: Market Domination Overtime
Nvidia down for third day, Arm joins Nasdaq 100: Market Domination Overtime
NEW YORK (AP) — Another slide for a Wall Street heavyweight Nvidia kept US indexes mixed on Monday, even as most stocks rose. The S&P 500 fell 0.3% to retreat further from the record set last week. The decline for Nvidia and other winners of Wall Street’s artificial intelligence boom dragged the Nasdaq composite down … Read more
Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., June 24, 2024. Brendan McDermid | Reuters This report is from today’s CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. … Read more
Three AI acquirers recently announced stock splits. But which one is better to buy today? With the AI revolution in full swing, stock prices of favored semiconductor stocks have been on the rise. In late May, I identified five AI stocks that needed to be split. Lo and behold, three have already announced splits since … Read more
Here are the biggest calls on Wall Street Monday: Jefferies reiterates Nvidia after buy Jefferies raised its price target on Nvidia to $150 a share from $135. “NVDA remains the king and maker – for example, we still see growth for MRVL and ALAB alongside NVDA, but NVDA’s decisions for each generation could change that … Read more
(Bloomberg) — Stocks rebounded from earlier losses as several other industries outside the tech world advanced, riding out a selloff that shaved almost $400 billion from Nvidia Corp.’s value. Most Read by Bloomberg While the S&P 500 eked out gains, a decline in the giant chip maker raised speculation that the growth in the industry … Read more
Alnylam stock rises on strong results in heart drug study 1 minute ago Shares of Alnylam Pharmaceuticals ( ALNY ) skyrocketed after the biopharma firm reported strong results from a late-stage study of its RNA interference drug for a rare heart disease. The company reported that a Phase 3 trial of its vutrisiran showed “a … Read more